Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 224

1.

The detection of ESR1/PGR/ERBB2 mRNA levels by RT-QPCR: a better approach for subtyping breast cancer and predicting prognosis.

Du X, Li XQ, Li L, Xu YY, Feng YM.

Breast Cancer Res Treat. 2013 Feb;138(1):59-67. doi: 10.1007/s10549-013-2432-2. Epub 2013 Feb 10.

PMID:
23397283
2.

PAM50 breast cancer subtyping by RT-qPCR and concordance with standard clinical molecular markers.

Bastien RR, Rodríguez-Lescure Á, Ebbert MT, Prat A, Munárriz B, Rowe L, Miller P, Ruiz-Borrego M, Anderson D, Lyons B, Álvarez I, Dowell T, Wall D, Seguí MÁ, Barley L, Boucher KM, Alba E, Pappas L, Davis CA, Aranda I, Fauron C, Stijleman IJ, Palacios J, Antón A, Carrasco E, Caballero R, Ellis MJ, Nielsen TO, Perou CM, Astill M, Bernard PS, Martín M.

BMC Med Genomics. 2012 Oct 4;5:44. doi: 10.1186/1755-8794-5-44.

3.

Comparison of immunohistochemistry with PCR for assessment of ER, PR, and Ki-67 and prediction of pathological complete response in breast cancer.

Sinn HP, Schneeweiss A, Keller M, Schlombs K, Laible M, Seitz J, Lakis S, Veltrup E, Altevogt P, Eidt S, Wirtz RM, Marmé F.

BMC Cancer. 2017 Feb 13;17(1):124. doi: 10.1186/s12885-017-3111-1.

4.

Technical validation of an RT-qPCR in vitro diagnostic test system for the determination of breast cancer molecular subtypes by quantification of ERBB2, ESR1, PGR and MKI67 mRNA levels from formalin-fixed paraffin-embedded breast tumor specimens.

Laible M, Schlombs K, Kaiser K, Veltrup E, Herlein S, Lakis S, Stöhr R, Eidt S, Hartmann A, Wirtz RM, Sahin U.

BMC Cancer. 2016 Jul 7;16:398. doi: 10.1186/s12885-016-2476-x.

5.

Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.

Pentheroudakis G, Kalogeras KT, Wirtz RM, Grimani I, Zografos G, Gogas H, Stropp U, Pectasides D, Skarlos D, Hennig G, Samantas E, Bafaloukos D, Papakostas P, Kalofonos HP, Pavlidis N, Fountzilas G.

Breast Cancer Res Treat. 2009 Jul;116(1):131-43. doi: 10.1007/s10549-008-0144-9. Epub 2008 Jul 31.

PMID:
18668363
6.

Triple-negative phenotype is of adverse prognostic value in patients treated with dose-dense sequential adjuvant chemotherapy: a translational research analysis in the context of a Hellenic Cooperative Oncology Group (HeCOG) randomized phase III trial.

Skarlos P, Christodoulou C, Kalogeras KT, Eleftheraki AG, Bobos M, Batistatou A, Valavanis C, Tzaida O, Timotheadou E, Kronenwett R, Wirtz RM, Kostopoulos I, Televantou D, Koutselini E, Papaspirou I, Papadimitriou CA, Pectasides D, Gogas H, Aravantinos G, Pavlidis N, Arapantoni P, Skarlos DV, Fountzilas G.

Cancer Chemother Pharmacol. 2012 Feb;69(2):533-46. doi: 10.1007/s00280-011-1730-9. Epub 2011 Sep 8.

PMID:
21901395
8.

Biological subtyping of early breast cancer: a study comparing RT-qPCR with immunohistochemistry.

Wirtz RM, Sihto H, Isola J, Heikkilä P, Kellokumpu-Lehtinen PL, Auvinen P, Turpeenniemi-Hujanen T, Jyrkkiö S, Lakis S, Schlombs K, Laible M, Weber S, Eidt S, Sahin U, Joensuu H.

Breast Cancer Res Treat. 2016 Jun;157(3):437-46. doi: 10.1007/s10549-016-3835-7. Epub 2016 May 24.

9.

Development of a robust RNA-based classifier to accurately determine ER, PR, and HER2 status in breast cancer clinical samples.

Wilson TR, Xiao Y, Spoerke JM, Fridlyand J, Koeppen H, Fuentes E, Huw LY, Abbas I, Gower A, Schleifman EB, Desai R, Fu L, Sumiyoshi T, O'Shaughnessy JA, Hampton GM, Lackner MR.

Breast Cancer Res Treat. 2014 Nov;148(2):315-25. doi: 10.1007/s10549-014-3163-8. Epub 2014 Oct 22.

10.

Increased insulin-like growth factor-1 receptor mRNA expression predicts poor survival in immunophenotypes of early breast carcinoma.

Peiró G, Adrover E, Sánchez-Tejada L, Lerma E, Planelles M, Sánchez-Payá J, Aranda FI, Giner D, Gutiérrez-Aviñó FJ.

Mod Pathol. 2011 Feb;24(2):201-8. doi: 10.1038/modpathol.2010.191. Epub 2010 Nov 5.

11.

Prognostic value of breast cancer subtypes, Ki-67 proliferation index, age, and pathologic tumor characteristics on breast cancer survival in Caucasian women.

Ferguson NL, Bell J, Heidel R, Lee S, Vanmeter S, Duncan L, Munsey B, Panella T, Orucevic A.

Breast J. 2013 Jan-Feb;19(1):22-30. doi: 10.1111/tbj.12059. Epub 2012 Dec 13.

PMID:
23240985
12.

Impact of triple negative phenotype on breast cancer prognosis.

Kaplan HG, Malmgren JA.

Breast J. 2008 Sep-Oct;14(5):456-63. doi: 10.1111/j.1524-4741.2008.00622.x. Epub 2008 Jul 24.

PMID:
18657139
13.

Prognostic significance of ESR1 gene amplification, mRNA/protein expression and functional profiles in high-risk early breast cancer: a translational study of the Hellenic Cooperative Oncology Group (HeCOG).

Pentheroudakis G, Kotoula V, Eleftheraki AG, Tsolaki E, Wirtz RM, Kalogeras KT, Batistatou A, Bobos M, Dimopoulos MA, Timotheadou E, Gogas H, Christodoulou C, Papadopoulou K, Efstratiou I, Scopa CD, Papaspyrou I, Vlachodimitropoulos D, Linardou H, Samantas E, Pectasides D, Pavlidis N, Fountzilas G.

PLoS One. 2013 Jul 29;8(7):e70634. doi: 10.1371/journal.pone.0070634. Print 2013.

14.

Quantitative Real Time PCR assessment of hormonal receptors and HER2 status on fine-needle aspiration pre-operatory specimens from a prospectively accrued cohort of women with suspect breast malignant lesions.

Garuti A, Rocco I, Cirmena G, Chiaramondia M, Baccini P, Calabrese M, Palermo C, Friedman D, Zoppoli G, Ballestrero A.

Gynecol Oncol. 2014 Feb;132(2):389-96. doi: 10.1016/j.ygyno.2013.11.020. Epub 2013 Nov 21.

PMID:
24269902
15.

An international reproducibility study validating quantitative determination of ERBB2, ESR1, PGR, and MKI67 mRNA in breast cancer using MammaTyper®.

Varga Z, Lebeau A, Bu H, Hartmann A, Penault-Llorca F, Guerini-Rocco E, Schraml P, Symmans F, Stoehr R, Teng X, Turzynski A, von Wasielewski R, Gürtler C, Laible M, Schlombs K, Joensuu H, Keller T, Sinn P, Sahin U, Bartlett J, Viale G.

Breast Cancer Res. 2017 May 11;19(1):55. doi: 10.1186/s13058-017-0848-z.

16.

Clinicopathological significance of β -tubulin isotype III gene expression in breast cancer patients.

He Q, Peng B, Zhuang D, Xiao L, Zheng L, Fan Z, Zhu J, Xu B, Xu C, Zhao J, Wu L, Zhou P, Hou L, Yu F, Zhao G.

Cancer Biomark. 2015;15(6):823-31. doi: 10.3233/CBM-150526.

PMID:
26406408
17.
18.

Quantitation of HDAC1 mRNA expression in invasive carcinoma of the breast*.

Zhang Z, Yamashita H, Toyama T, Sugiura H, Ando Y, Mita K, Hamaguchi M, Hara Y, Kobayashi S, Iwase H.

Breast Cancer Res Treat. 2005 Nov;94(1):11-6.

PMID:
16172792
19.

RNA-based determination of ESR1 and HER2 expression and response to neoadjuvant chemotherapy.

Denkert C, Loibl S, Kronenwett R, Budczies J, von Törne C, Nekljudova V, Darb-Esfahani S, Solbach C, Sinn BV, Petry C, Müller BM, Hilfrich J, Altmann G, Staebler A, Roth C, Ataseven B, Kirchner T, Dietel M, Untch M, von Minckwitz G.

Ann Oncol. 2013 Mar;24(3):632-9. doi: 10.1093/annonc/mds339. Epub 2012 Nov 6.

PMID:
23131391
20.

Different prognostic value of cytokeratin-19 mRNA positive circulating tumor cells according to estrogen receptor and HER2 status in early-stage breast cancer.

Ignatiadis M, Xenidis N, Perraki M, Apostolaki S, Politaki E, Kafousi M, Stathopoulos EN, Stathopoulou A, Lianidou E, Chlouverakis G, Sotiriou C, Georgoulias V, Mavroudis D.

J Clin Oncol. 2007 Nov 20;25(33):5194-202. Epub 2007 Oct 22.

PMID:
17954712

Supplemental Content

Support Center